Skip to main content
. 2004 Mar 30;90(8):1479–1485. doi: 10.1038/sj.bjc.6601753

Table 4. Time from presentation to treatment for presenting colorectal cancer symptoms and other clinical variables.

    Days from presentation to treatment-geometric mean (95% CI)
 
N=1071 Number with symptom (%) With Without P-value
Abdominal pain 318 (30) 102 (83–125) 158 (144–173) <0.001
Palpable abdominal mass 40 (4) 32 (22–48) 147 (134–160) <0.001
Rectal bleeding 286 (27) 105 (92–120) 153 (137–171) <0.001
Rectal mass 31 (3) 46 (35–59) 143 (131–157) <0.001
Guarding 6 (1) 22 (0.9–540) 140 (128–153) 0.003
Nausea 36 (3) 77 (39–153) 141 (129–155) 0.017
Rectal mucus discharge 47 (4) 85 (60–122) 142 (129–155) 0.023
Tenesmus 29 (3) 76 (49–116) 141 (129–154) 0.028
Increased frequency of bowel movements 67 (6) 99 (72–135) 142 (129–156) 0.057
Abdominal distension 60 (6) 98 (57–170) 141 (129–155) 0.066
Vomiting 83 (8) 105 (65–170) 142 (130–155) 0.083
         
Number of symptoms at presentation       <0.001
 0 26 (2) 57 (27–119)  
 1 459 (43) 208 (184–235)  
 2 332 (31) 133 (114–156)  
 3 150 (14) 104 (83–131)  
 4 or more 104 (10) 49 (36–68)  
         
History of anxiety or depression 143 (13) 210 (167–264) 130 (118–143) <0.001
Past history of benign bowel disease 168 (16) 169 (133–215) 133 (121–147) 0.059
         
GP consultations/month       <0.001
 0–0.5 248 (23) 620 (571–673)  
 0.5–2.5 247 (23) 182 (164–202)  
 2.5–10 222 (21) 92 (82–105)  
 >10 283 (26) 49 (40–59)  
         
Tumour site       0.072
 Right side colon to hepatic flexure 263 (25) 163 (136–197)  
 Transverse colon to splenic flexure 105 (10) 102 (73–141)  
 Descending and sigmoid colon 286 (27) 140 (116–170)  
 Rectosigmoid and rectum 379 (35) 136 (120–154)  
 Unspecified or overlapping 38 (4) 111 (66–188)  

No differences (P>0.10) for rectal or anal discomfort, melaena, breathlessness, pallor, tiredness, anaemia, weight loss, anorexia, unspecified changes in bowel habit, urgency, diarrhoea, constipation, nonspecific anal symptoms, faecal incontinence or discharge, iron medication at time of presentation, or previous benign colorectal investigations.

HHS Vulnerability Disclosure